SCHEMBL595155

SCHEMBL595155

CCOC(=O)COC(=O)N1CCN(c2ccc(-c3cccc(C(F)(F)F)c3)nc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 6/20 0.48
MAPK1 P28482 2/20 0.48
RAB9A P51151 2/20 0.48
HTT P42858 3/20 0.47
USP2 O75604 1/20 0.47
MAPT P10636 4/20 0.47
KDM4E B2RXH2 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 2/20 0.44
GRIN1 Q05586 2/20 0.44
GRIN2B Q13224 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL594736 0.88 LMNA (0.50) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL595284 0.88 ALDH1A1 (0.48) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL594735 0.85 CNR2 (0.54) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL593921 0.83 SMN1; SMN2 (0.64) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL5230452 0.81 SLC6A7 (0.49) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL9401009 0.78 ALDH1A1 (0.59) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL594757 0.75 MAPT (0.54) ALDH1A1HPGDSMN1; SMN2LMNAMAPK1
SCHEMBL14341343 0.74 WNT3A (0.40) ALDH1A1HPGDSMN1; SMN2LMNAMAPK1
SCHEMBL593524 0.74 SMN1; SMN2 (0.73) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL594530 0.74 ALDH1A1 (0.53) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114866-B2 Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme SANOFI-AVENTIS (FR) 2012-02-14 US disclosed
US-20100137329-A1 DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME SANOFI-EVENTIS (FR) 2010-06-03 US disclosed
US-7687503-B2 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders SANOFI-AVENTIS (FR) 2010-03-30 US disclosed
US-20060293310-A1 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders SANOFI-AVENTIS (FR) 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137329-A1 DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME FAAH, FAAH2, CNR1 ALDH1A1 152/4885HPGD 198/4885SMN1; SMN2 2237/4885
US-20060293310-A1 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders FAAH, FAAH2, APEH ALDH1A1 461/4885HPGD 973/4885SMN1; SMN2 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.